Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,844,724
  • Shares Outstanding, K 107,700
  • Annual Sales, $ 5,872 M
  • Annual Income, $ 1,199 M
  • 36-Month Beta 1.46
  • Price/Sales 5.79
  • Price/Cash Flow 19.91
  • Price/Book 5.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
311.34 +1.51%
on 04/20/18
346.87 -8.89%
on 03/29/18
-5.25 (-1.63%)
since 03/23/18
3-Month
311.34 +1.51%
on 04/20/18
396.22 -20.24%
on 01/25/18
-65.67 (-17.20%)
since 01/23/18
52-Week
311.34 +1.51%
on 04/20/18
543.55 -41.86%
on 06/22/17
-54.08 (-14.61%)
since 04/21/17

Most Recent Stories

More News
Look for Shares of Regeneron Pharm to Potentially Rebound after Yesterday's 1.49% Sell Off

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $315.60 to a high of $322.69. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of...

REGN : 315.20 (+0.30%)
Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now?

Smart Beta ETF report for PBE

PBE : 48.61 (-0.12%)
ILMN : 244.56 (-0.02%)
IBB : 104.62 (-0.32%)
VRTX : 157.92 (-0.15%)
REGN : 315.20 (+0.30%)
XBI : 87.48 (-1.63%)
Free Research Reports on These Biotech Stocks -- Regeneron Pharma, Sangamo Therapeutics, Seattle Genetics, and Spectrum Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on REGN, SGMO, SGEN, and SPPI which can be accessed for free by signing up to www.wallstequities.com/registration....

SGMO : 17.80 (-6.56%)
SPPI : 17.89 (-3.14%)
SGEN : 49.43 (-0.50%)
REGN : 315.20 (+0.30%)
FDA Restricts Sale of Bayer's Essure Birth Control Device

FDA puts restriction on the sale of Bayer's (BAYRY) implanted birth control device Essure.

BAYRY : 30.1500 (-0.94%)
LGND : 165.79 (-0.71%)
REGN : 315.20 (+0.30%)
MON : 124.67 (-0.26%)
FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

LGND : 165.79 (-0.71%)
ENTA : 87.40 (-0.10%)
REGN : 315.20 (+0.30%)
PCRX : 35.55 (-1.25%)
Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 3, 2018, before the U.S. financial markets open....

REGN : 315.20 (+0.30%)
Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why

Let us look at the factors that have led to the increase in share price of Emergent (EBS).

LGND : 165.79 (-0.71%)
ENTA : 87.40 (-0.10%)
EBS : 54.15 (-0.18%)
REGN : 315.20 (+0.30%)
Novo Nordisk Obtains Licence for Sickle Cell Disease Program

Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

LGND : 165.79 (-0.71%)
NVO : 47.18 (-0.11%)
ENTA : 87.40 (-0.10%)
REGN : 315.20 (+0.30%)
Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel

Sonoma's (SNOA) shares gain after the FDA approves its antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures.

LGND : 165.79 (-0.71%)
NVS : 77.85 (-0.04%)
SNOA : 3.90 (-1.02%)
REGN : 315.20 (+0.30%)
Catalyst (CPRX) Up on New Drug Application for Firdapse

Catalyst (CPRX) new drug application for its lead pipeline candidate keeps it on a growth trajectory.

LGND : 165.79 (-0.71%)
BMRN : 82.18 (-0.15%)
REGN : 315.20 (+0.30%)
CPRX : 2.54 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 321.44
1st Resistance Point 317.85
Last Price 315.20
1st Support Level 311.00
2nd Support Level 307.74

See More

52-Week High 543.55
Fibonacci 61.8% 454.85
Fibonacci 50% 427.45
Fibonacci 38.2% 400.04
Last Price 315.20
52-Week Low 311.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar